Bluebird spinoff 2seventy bio launches

By The Science Advisory Board staff writers

November 4, 2021 -- Bluebird Bio spinoff 2seventy bio has officially launched as an independent, publicly traded company and will trade on the Nasdaq Global Select Market starting November 5 under the ticker symbol TSVT.

2seventy's pipeline includes a range of candidates for use in treating hematologic and solid tumors, including two therapies that are projected to enter trials in the first half of 2022. The company's portfolio also includes a development and commercialization partnership in the U.S. with Bristol Myers Squibb (BMS) for Abecma, a B-cell maturation, antigen-directed, CAR T-cell immunotherapy for multiple myeloma.

Abecma generated $67 million in U.S. sales in the third quarter of 2021, its first full quarter after launch, 2seventy said. BMS and 2seventy are pursuing additional clinical studies in earlier lines of treatment for patients with multiple myeloma, the company said.

Resilience to acquire Bluebird facility, partner on vector manufacturing
Bluebird Bio and National Resilience have formed a strategic alliance to accelerate the early research, development, and delivery of next-generation cell...
Bluebird Bio to split business
Bluebird Bio announced that it will separate its severe genetic and oncology businesses into two distinct and independent publicly traded companies. Bluebird...
Magenta Therapeutics, Bluebird Bio to test stem cell mobilization combo in clinic
Magenta Therapeutics and Bluebird Bio have entered an exclusive clinical trial collaboration to evaluate MGTA-145, Magenta's chemokine receptor, in combination...
Bluebird Bio gets gene therapy EMA marketing nod accepted
The European Medicines Agency (EMA) accepted Bluebird Bio's marketing authorization application for its investigational elivaldogene autotemcel gene therapy...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter